Innogene
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Innogene makes cosmeceutical products, a category blending cosmetics with pharmaceutical-grade ingredients, focused on hair-loss relief and problem-skin care, including scalp treatments, home-care kits, scalp-care devices, health supplements, and pharmaceuticals.
It supplies clinics and hospitals across South Korea and exports to markets including the United States, China, Singapore, Hong Kong, and Malaysia. Listed on KOSDAQ, South Korea's tech and small-cap board, the company earns the large majority of its revenue from its hair-loss product line, with skin-beauty products making up the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
Innogene in five facts
What does Innogene do?
Innogene makes cosmeceutical products, a category blending cosmetics with pharmaceutical-grade ingredients, focused on hair-loss relief and problem-skin care, including scalp treatments, home-care kits, scalp-care devices, health supplements, and pharmaceuticals.
Where is Innogene listed and in which sector?
Innogene (Korean name: 이노진) trades under KRX code 344860 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is Innogene?
Its market capitalisation was US$16.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Innogene's latest annual revenue and operating profit?
For fiscal year 2025, Innogene reported revenue of US$6.2M, operating profit of US$3.4K and net income of US$217.3K, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 8.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Sep 22
- Material event report (treasury share acquisition)
Innogene disclosed a plan to buy back its own shares worth US$708K, about 5.2% of its market value.
Treasury Shares · Aug 11 - Material event report (rights offering)
Innogene disclosed a private placement (third-party allotment) to raise US$591K, about 4.3% of its market value.
Capital raise · Aug 7 - [Amended] Material event report (rights offering)
Innogene updated the terms of a private placement (third-party allotment) to raise US$2.37M, about 17.3% of its market value.
Capital raise · Jul 31 · 2 versions - Agreement on change of control signed
Innogene's controlling stake is set to change hands from an individual to Metamorphosys Co., Ltd., Jeong Gi-cheol, in a deal worth US$2.17M.
Ownership change · Jun 30 - Treasury share acquisition: results reportTreasury Shares · Jun 25
- Material event report (treasury share acquisition)
Innogene disclosed a plan to buy back its own shares worth US$332K, about 2.6% of its market value.
Treasury Shares · May 19 - Supply contract signed (voluntary)
Innogene disclosed a supply contract with Dareum Daleum Co., Ltd., worth US$292K, about 5.4% of its recent annual revenue, running through May 2026.
Supply contract · Apr 1 - Cash/in-kind dividend decision
Innogene declared a cash dividend of US$0.06 per share.
Dividend · Feb 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Innogene reported separate results for FY2025: revenue of US$5.61M (−8.4% year on year), operating profit of US$23.8K (−94.5% year on year) and net income of US$200K (−69.1% year on year).
Earnings · Feb 5